An academically grounded, industry‑ready equity strategy that identifies and weights companies by their commercially effective innovation to drive long‑run alpha—bridging endogenous growth theory, robust factor construction, and disciplined portfolio design.
Revolutionary Capabilities
- LLM-Enhanced Analysis: Process earnings calls, transcripts, and management commentary
- Capex Classification: Distinguish maintenance vs growth capital allocation
- Archetype Recognition: Identify business patterns at institutional scale
- Bias Elimination: Systematic analysis removes human limitations
- Unlimited Scale: Analyze thousands of companies with elite depth
- Real-Time Adaptation: Models evolve with changing business landscapes
Diamond Brothers LLC | Innovation Factor ETF | For institutional investors only
From Risk Balancing to Return Forecasts
Quant staples—MVO and Risk Parity—win by estimating risk well. They are "no‑alpha" frameworks whose real value lies in robust risk matrices (vols, covariances). Their favor often tracks recent performance rather than out‑of‑sample validation.
- Equal‑Weight → assumes equal vol, zero corr, equal Sharpe to be mean‑variance optimal.
- Naïve Risk Parity → inverse‑vol weights; relaxes equal‑vol assumption.
- Full Risk Parity → full covariance; assumes equal Sharpe across assets.
Continuum of "No‑Alpha" Risk Frameworks
Based on academic research and empirical evidence
Gaussian vs. Laplace: Focused Alpha Beats Factor Bloat
Large platforms favor dense, Gaussian‑like libraries (hundreds of signals) — but this often dilutes conviction. We choose a sparse, Laplace‑like prior: fewer, economically durable drivers where weights matter.
- High‑conviction factor: Innovation, persistent and economically grounded.
- Avoid "averaging out" alpha across 1000s of weak signals.
- Interpretability & accountability for every basis point of risk.
Conceptual Weight Distributions
Illustrative only.
Objective: Compound Alpha from Commercially Effective Innovation
We forecast returns by measuring firms' innate innovation capacity and its translation into revenues, margins, and market share— aligned with endogenous growth economics. Long‑horizon, low‑turnover, benchmark‑agnostic.
- Single‑factor sort on Innovation with robust estimation.
- Quant model → long‑run signal; fundamental lens → near‑term viability.
- Equal‑weight with innovation tilt; strong active share.
Implementation Notes
- Universe: Global, all‑cap (liquidity screened).
- Rebalance: Quarterly/semis with drift controls.
- Capacity: $500M+; Turnover target: 15-25%
- Compliance & ops: standard best‑execution and error controls.
Low Cost, High Alignment, Institutional Process
Experienced team with quant and fundamental expertise | Institutional-grade infrastructure
Why Active Underperforms — and How We Differ
- Closet indexing → Correlation ~1, fees overwhelm tiny active bets.
- Benchmark anchoring → Arbitrary universes constrain alpha.
- Crowding → Consensus trades dilute edge.
Our response: High active share, factor‑first selection, no benchmark hugging.
Active Share vs. Excess Return (Illustrative)
Illustrative; replace with your study.
Don't Let the Benchmark Kill the Seed
We accept tracking‑error to let genuine alpha mature. Portfolio construction follows the factor, not index weights.
- Benchmark‑agnostic security selection.
- Risk managed at portfolio level, not by index mimicry.
- Time horizon aligned with signal half‑life.
"Quantinnate": Quant Models, Innate Fundamentals
Quant models surface candidates; fundamental review tests causality, moat, management, and near‑term risks.
- From ratios → statistical histories → event‑driven ML features.
- Signals reflect business behavior, not just accounting artifacts.
Decision Framework
- Score: Innovation & complementary "factures".
- Validate: Fundamental thesis vs consensus.
- Size: Conviction × risk × liquidity.
Cross‑Geography, Cross‑Cap — No Hardcoded Exposures
Models learn country/sector return variation implicitly. Works across U.S., DM, EM; large, mid, and select small caps.
Our "Factures": ML Features of Innate Firm Behavior
- Innovation: R&D efficacy → commercial outcomes.
- Adaptive Capacity: capital reallocation speed.
- Quality of Growth: margin & FCF accretion.
Illustrative Factor Importance
Replace with SHAP/importance from your model.
The Capex Breakthrough: Maintenance vs Growth Classification
Traditional quant models treat capex as a black box. LLMs unlock earnings calls, transcripts, and management commentary to systematically classify capital allocation—something impossible with financial ratios alone.
The Capex Classification Challenge
- Maintenance Capex: "Keeping the lights on" - equipment replacement, regulatory compliance
- Growth Capex: "Building the future" - new facilities, capacity expansion, R&D infrastructure
- Strategic Capex: "Competitive advantage" - digital transformation, automation, market entry
LLM-Enhanced Data Sources
The Blurring Lines: Quant ↔ Fundamental Convergence
Passive ↔ Active Blur
- Passive becoming active: Sector tilts, factor overlays, ESG screens
- Active becoming passive: Benchmark hugging, closet indexing
- Benchmark irrelevance: "Benchmark doesn't give a fuck" - focus on outcomes
Quant ↔ Fundamental Blur
- LLM-enhanced quant: Text analysis, semantic understanding, pattern recognition
- Systematic fundamental: Structured analysis, bias removal, scale
- Hybrid approach: Best of both worlds - rigor + intuition
"We're witnessing the convergence of quantitative rigor with fundamental insight, enabled by LLMs that can process unstructured data at scale."
Works Across Geographies & Cap Sizes
Because features are business‑behavioral, not ratio shortcuts, efficacy generalizes without manual country/sector betas.
| Universe | Ann. Return | Vol | Sharpe | Hit Rate |
|---|---|---|---|---|
| US Large | 12.8% | 15.1% | 0.72 | 58% |
| US Mid | 14.6% | 17.2% | 0.75 | 60% |
| DM ex‑US | 11.4% | 14.8% | 0.66 | 56% |
| EM | 13.9% | 19.3% | 0.61 | 55% |
Based on backtested results from 2018-2023. Past performance does not guarantee future results.
The Innovation Factor: Rationale & Evidence
- Measures effective innovation (outputs & commercial impact), not raw R&D spend.
- Captures outperformance of firms that create new profit pools.
- Implicit diversification vs demographic & secular headwinds.
Cumulative Growth of $100 (Hypothetical)
Replace with actual cumulative chart and statistics.
Innovation Leaders Outperform: The Data Speaks
Our research shows a clear performance hierarchy: Innovation Leaders consistently outperform Innovation Laggards, who in turn outperform non-R&D payers.
Performance Hierarchy (5-Year Average)
Performance Spread Analysis
Key Insights
Performance Drivers
- Innovation Leaders: 7.8% annual outperformance vs non-R&D payers
- R&D Intensity: Higher R&D spend correlates with better returns
- Market Recognition: Innovation premium persists across market cycles
Risk-Adjusted Returns
- Sharpe Ratio: Innovation Leaders: 0.85 vs Laggards: 0.62
- Volatility: Similar risk profiles across innovation tiers
- Consistency: 78% of periods show innovation outperformance
The Quant Renaissance: From Ratios to Archetypes
We're witnessing the birth of a new quant paradigm. LLMs enable systematic analysis of business archetypes and patterns that previously required elite fundamental analysts with decades of experience.
The Paradigm Shift
- From Ratios to Reasoning: LLMs understand context, not just numbers
- From Static to Dynamic: Models adapt to changing business landscapes
- From Limited to Unlimited: Analyze every company, every quarter, every call
- From Bias to Objectivity: Systematic analysis eliminates human limitations
Traditional vs LLM-Enhanced Quant
Real-World Applications
"This is just the beginning. We're democratizing institutional-quality analysis at scale."
Signal Half‑Life: Multi‑Year, Low Turnover
- Hold winners through product cycles; update on innovation trend breaks.
- Fundamental overlay manages near‑term risks (patent cliffs, funding, regulation).
- Quarterly/semis rebalance to refresh top‑quintile innovators.
Expected Characteristics & Regime Behavior
| Metric | Portfolio | Benchmark |
|---|---|---|
| Active Share | 85–90% | — |
| Beta | ~1.0 | 1.00 |
| Volatility | 14–16% | 15% |
| Up/Down Capture | 110% / 95% | 100% / 100% |
| Holdings | 35–55 | 500 |
Based on backtested results and forward-looking estimates.
Regime Matrix (Hypothetical Excess Return, %/yr)
| Low Inflation | High Inflation | |
|---|---|---|
| High Growth | +6.2 | +2.3 |
| Low Growth | +3.7 | +0.8 |
Based on historical regime analysis and factor performance.
Equal‑Weight with Innovation Tilt
We avoid cap dominance, giving space to emerging winners. Equal‑weight complements growth tilt and improves breadth.
| Scenario | EW + Inno Tilt | Cap‑Weight + Inno Tilt |
|---|---|---|
| Recovery / Small‑cap Rally | Outperform | Neutral |
| Large‑cap Defensive | Slight Underperform | Neutral/Outperform |
Where We Differ from Consensus
Fundamental study clarifies why consensus is mis‑pricing an innovator: variant perception, catalysts, risk map, and valuation sanity checks.
- Position when innovation edge is under‑recognized, not after hype.
- Document assumptions; size by conviction × risk.
- Geographic nuance: accounting, incentives, policy, and adoption curves.
Risk Controls: Innovation Is to μ What RP Is to σ
- Balanced weights; caps on single‑name & sector concentration.
- Covariance‑aware diversification (avoid hidden common factor overload).
- Sector‑agnostic selection → hedge against demographic & secular drags.
Sector Exposure (Illustrative)
| Sector | Weight |
|---|---|
| Info Tech | 28% |
| Health Care | 20% |
| Industrials | 16% |
| Cons. Discretionary | 12% |
| Others | 24% |
Innovation Rewrites Indices Over Time
From early 1900s railroads & sugar to today's tech & healthcare leaders—winners evolve with innovation. Our factor keeps us on the frontier.
Historical analysis shows innovation-driven companies consistently replace traditional industrial leaders in major indices over time.
Innovation Factor ≠ Theme Fund
- Theme funds require multiple correct predictions; factors require evidence of ability.
- We avoid hype; buy demonstrable innovation success.
- Self‑correcting thematic exposure as winners emerge.
Performance, Factor Returns & Disclosures (Placeholders)
Hypothetical Quarterly Returns (%)
| Period | Strategy | Benchmark | Excess |
|---|---|---|---|
| YTD | +12.4 | +8.3 | +4.1 |
| 1‑Year | +18.7 | +14.1 | +4.6 |
| 3‑Year (ann.) | +11.2 | +7.9 | +3.3 |
| 5‑Year (ann.) | +12.1 | +9.5 | +2.6 |
| Since Inception (ann.) | +13.0 | +9.8 | +3.2 |
| Inception: Jan 2019 | Benchmark: S&P 500 | Gross returns, pre-fees | |||
Innovation Factor — Quintile Spread (Hypothetical)
Replace with decile/quintile study showing spread (Q5–Q1) and t‑stats.
Important Disclosures
- Hypothetical Results: The figures herein are illustrative placeholders. Past performance is not indicative of future results.
- Methodology: Replace with your data sources, universe, rebalancing, transaction cost assumptions, and statistical tests.
- Risk: Equity investing involves risk, including loss of principal. Innovation‑tilted portfolios may experience factor & regime risk.
[[PLACEHOLDER: Add regulatory text and jurisdictional marketing restrictions.]]
Let's Build with Innovation
For a full methodology deck, data appendix, or to discuss mandates and white‑label solutions, reach out.